Compare GABC & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GABC | NRIX |
|---|---|---|
| Founded | 1910 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | 1995 | 2020 |
| Metric | GABC | NRIX |
|---|---|---|
| Price | $44.29 | $17.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 12 |
| Target Price | ★ $46.50 | $30.50 |
| AVG Volume (30 Days) | 127.0K | ★ 1.2M |
| Earning Date | 04-27-2026 | 04-08-2026 |
| Dividend Yield | ★ 2.81% | N/A |
| EPS Growth | ★ 8.13 | N/A |
| EPS | ★ 3.06 | N/A |
| Revenue | ★ $487,401,000.00 | $76,987,000.00 |
| Revenue This Year | $16.89 | N/A |
| Revenue Next Year | $3.94 | $48.05 |
| P/E Ratio | $14.42 | ★ N/A |
| Revenue Growth | 37.80 | ★ 99.31 |
| 52 Week Low | $35.04 | $8.20 |
| 52 Week High | $45.00 | $22.50 |
| Indicator | GABC | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 64.17 | 59.28 |
| Support Level | $37.47 | $16.81 |
| Resistance Level | $44.77 | $19.98 |
| Average True Range (ATR) | 0.79 | 0.91 |
| MACD | 0.11 | 0.20 |
| Stochastic Oscillator | 83.95 | 76.12 |
German American Bancorp Inc is a bank holding company. The lines of business include the core banking segment and the wealth management segment. The core banking segment involves attracting deposits from the general public and using those funds to originate consumer, commercial, and agricultural real estate, and residential mortgage loans. These core banking activities also include the sale of residential mortgage loans in the secondary market. Wealth management services, which involve providing trust, investment advisory, brokerage, and retirement planning services to customers. The company generates the majority of its revenue from the core banking segment.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.